Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kontafarma China HoldingsHKSE:01312 -3.45% Median PS Value is HK$0.07 as of Aug. 07, 2026, which is 100% below its 10-year median of 0.29. The stock has 3 warning signs investors should review. Among 540 Drug Manufacturers companies, Kontafarma China Holdings ranks better than 86.3% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Kontafarma China Holdings's Median PS Value or its related term are showing as below:
HKSE:01312'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23 Med: 0.29 Max: 0.41
Current: 0.4
During the past 13 years, the highest Price to Median PS Value of Kontafarma China Holdings was 0.41. The lowest was 0.23. And the median was 0.29.
HKSE:01312's Price-to-Median-PS-Value is ranked better than 86.3% of 540
companies
in the Drug Manufacturers industry
Industry Median: 0.865
vs HKSE:01312: 0.40
Kontafarma China Holdings (HKSE:01312) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Kontafarma China Holdings's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.028
/
0.07
=
0.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontafarma China Holdings Median PS Value Related Terms
Kontafarma China Holdings Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontafarma China Holdings Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Kontafarma China Holdings's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.4268.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kontafarma China Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.164.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontafarma China Holdings (HKSE:01312) has a Median PS Value of HK$0.07 as of Aug. 07, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kontafarma China Holdings and its competitors. This is 76% below median its historical median of 0.29. Over the past decade, Kontafarma China Holdings' Median PS Value has ranged from 0.23 to 0.41. According to the industry distribution chart, Kontafarma China Holdings ranks #74 out of 540 companies in the Drug Manufacturers industry, placing it in the top 13.7%.
Is Kontafarma China Holdings' Median PS Value too high?
Kontafarma China Holdings' current Median PS Value of HK$0.07 is 76% below median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 0.41. Based on the distribution chart, Kontafarma China Holdings ranks #74 out of 540 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Kontafarma China Holdings' Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kontafarma China Holdings ranks #74 out of 540 companies for Median PS Value. This places Kontafarma China Holdings in the top 14% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.87. Historically, Kontafarma China Holdings' own Median PS Value has ranged from 0.23 to 0.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.87, based on 540 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Kontafarma China Holdings and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kontafarma China Holdings's current Median PS Value is HK$0.07, which is 76% below median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 30% below its estimated fair value. The current Median PS Value is HK$0.07, which is 76% below median its 10-year median of 0.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current Median PS Value is HK$0.07 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01312 has been successfully added to your 
